PROGRAM

Lunch symposium

  • 臺灣百靈佳殷格翰  Boehringer Ingelheim Taiwan
  • ROOM 102
  • 2018/11/24 12:30-13:30

Session Chair/ Opening /Closing Remark: Dr. Jie-Yuan Li

  • Professor Mark Edwards
  • Can dopamine agonists ameliorate both the motor and non-motor symptoms of Parkinson’s disease?
  • PhD, MRCP, FRCP
    Honorary Consultant Neurologist
    Atkinson Morley Regional Neuroscience Centre, St George's Hospital
    Professor
    Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St George's University
    United Kingdom
    E-mail:medwards@sgul.ac.uk
  • 晟德大藥廠  Center Laboratories
  • North Lounge, 3F
  • 2018/11/24 12:30-13:30

Session Chair/ Opening /Closing Remark: Dr. Yi-Ting Hsu

  • Professor Simon Lewis
  • Efficacy of MAOB inhibitors for the treatment of Parkinson’s disease-an update view
  • MD
    Consultant Neurologist
    Royal Prince Alfred Hospital
    Professor
    Brain and Mind Centre, University of Sydney
    Australia
    E-mail:profsimonlewis@gmail.com
  • 博洽 Pro Chime Enterprise Corp
  • North Lounge, 3F
  • 2018/11/24 12:30-13:30

Session Chair/ Opening /Closing Remark: Dr. Jui-Cheng Chen

  • Professor Takaomi Taira
  • MRI-guided focus ultrasound for the treatment of movement disorders
  • MD, PhD
    Director and Professor
    Stereotactic and Functional Neurosurgery, Department of Neurosurgery, Tokyo Women's Medical University
    Japan
    E-mail:ttaira@twmu.ac.jp
  • 艾伯維藥廠  AbbVie Biopharmaceuticals
  • ROOM 201 BC
  • 2018/11/25 11:30-12:30

Session Chair/ Opening /Closing Remark: Professor Shey-Lin Wu

  • Professor Victor Fung
  • The role of LCIG (levodopa Carbidopa Intestinal Gel) in the treatment of advanced Parkinson’s disease
  • PhD, FRACP
    Director
    Movement Disorders Unit, Department of Neurology, Westmead Hospital
    Clinical Associate Professor
    Sydney Medical School, The University of Sydney
    Australia
    E-mail:vscfung@ozemail.com.au
  • 荷商葛蘭素史克藥廠  GlaxoSmithKline
  • ROOM 201 DE
  • 2018/11/25 11:30-12:30

Session Chair/ Opening /Closing Remark: Dr. Sheng-Huang Lin

  • Professor Thomas Kimber
  • Comparison of controlled- and immediate-release dopamine agonists in the treatment of Parkinson’s disease
  • MD, PhD
    Director
    Parkinson's Disease Clinic Neurology Unit, Royal Adelaide Hospital
    Clinical Associate Professor
    School of Medicine, Adelaide University
    Australia
    E-mail:Thomas.Kimber@sa.gov.au
  • 臺灣愛力根  Allergan Pharmaceuticals Taiwan
  • North Lounge, 3F
  • 2018/11/25 11:30-12:30

Session Chair/ Opening /Closing Remark: Dr. Wen-Juh Hwang

  • Jörg Wissel
  • The challenge of botulium toxins injection in difficulty situation of dystonia and spasticity
  • MD, FRCP
    Head
    Neurological Rehabilitation and Physical Therapy Department of Neurology, Vivantes Hospital
    Professor
    Human Science Faculty, Sportsmedicin, University of Potsdam
    Germany
    E-mail:Joerg.Wissel@vivantes.de
  • 台灣優時比  UCB Pharmaceuticals Taiwan
  • South Lounge, 3F
  • 2018/11/25 11:30-12:30

Session Chair/ Opening /Closing Remark: Dr. Han-Cheng Wang

  • Professor Jin Whan Cho
  • Rotigotine transdermal patch effect on motor and non-motor symptoms of Parkinson’s disease
  • MD, PhD
    Associate Professor
    Department of Neurology, Sungkyunkwan University
    Chair
    Scientific Committee, Korean Movement Disorder Society
    Korea
    E-mail:praisecho@hanmail.net